3 results match your criteria: "Heibei Eye Hospital[Affiliation]"
The role of serum metrics in anti- VEGF treatment for macular edema induced by retinal vein occlusion.
BMC Ophthalmol
April 2023
Heibei Eye Hospital, Number 399 quan bei dong da jie, Xingtai, Hebei Province, 054001, China.
Aim: To evaluate association between pretreatment serum metrics and best corrected visual acuity ( BCVA) of patients with macular edema secondary to retinal vein occlusion and its subtypes after intravitreal ranibizumab or conbercept implant.
Methods: This prospective research included 201 patients(201 eyes) who were diagnosed with macular edema secondary to retinal vein occlusion at Heibei Eye Hospital between January 2020 and January 2021, who all received intravitreal anti- vascular endothelial growth factor treatment. Serum metrics were measured before the first treatment, and correlations between BCVA and each of four parameters- platelets, neutrophil- to- lymphocyte ratio(NLR), platelet- to- lymphocyte ratio(PLR) and monocyte- to- lymphocyte ratio(MLR)- were analyzed to identify predictors of effective intravitreal injection treatment outcomes.
Analysis on short-term change of macular function and the correlates after intravitreal conbercept for CRVO-ME.
BMC Ophthalmol
April 2022
The Key Laboratory of Ocular of Heibei Province, The Treatment Centre of Ocular Disease of Hebei Province, Heibei Eye Hospital, Number 399 quan bei dong da jie, Xingtai, 054001, Hebei Province, China.
Article Synopsis
- The study aimed to investigate the short-term effects of intravitreal conbercept on macular function in patients with central retinal vein occlusion and macular edema.
- Twenty-three patients were evaluated for visual acuity, central macular thickness, and specific wave parameters before and after treatment; significant improvements were observed after one week and two months.
- Despite improvements in visual acuity and macular structure, there was no significant correlation found between the functional changes of the macula and changes in visual acuity or structure.
Design and Methodology of a Multi-Centre Clinical Trial of Low Dose Laser Cycloplasty for the Treatment of Malignant Glaucoma in China.
Ophthalmic Epidemiol
October 2022
Department of Glaucoma, The Eye Hospital of Wenzhou Medical University, Zhejiang Eye Hospital, Wenzhou, Zhejiang Province, China.
Article Synopsis
- The trial aims to assess the efficacy and safety of low dose laser cycloplasty (LCP) for treating malignant glaucoma.
- The study is a prospective, multicentre, non-controlled clinical trial, enrolling 34 patients from eight ophthalmic centers in China, focusing on those inadequately controlled by medical therapy.
- The primary outcome is the resolution of malignant glaucoma, defined by central anterior chamber deepening after LCP, with follow-up planned for 12 months, potentially offering a new treatment option for clinicians.